EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Depression and treatment with anti‐calcitonin gene related peptide ( CGRP) (ligand or receptor) antibodies for migraine

Simone de Vries Lentsch iD, Britt W H van der Arend, Irene de Boer, Erik W van Zwet, Antoinette MaassenVanDenBrink, Gisela M Terwindt

European Journal of Neurology · 2024-02 · 31 (2)

DOI: 10.1111/ene.16106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 17.10.2023. Verfasst von Simone de Vries Lentsch und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose The aim was to evaluate the effect of anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies on depressive symptoms in subjects with migraine and to determine whether depressive symptoms predict treatment response.

Methods

Patients with migraine treated with erenumab and fremanezumab at the Leiden Headache Centre completed daily E‐headache diaries. A control group was included. Depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS) and the Center for Epidemiological Studies Depression Scale (CES‐D) questionnaires at baseline (T0) and after 3 months (T1). First, the effect of treatment on the reduction in HADS‐D and CES‐D scores was assessed, with reduction in depression scores as the dependent variable and reduction in monthly migraine days (MMD) and treatment with anti‐CGRP medication as independent variables. Second, depression as a predictor of treatment response was investigated, using the absolute reduction in MMD as a dependent variable and age, gender, MMD, active depression, impact, stress and locus of control scores as independent variables.

Results

In total, n = 108 patients were treated with erenumab, n = 90 with fremanezumab and n = 68 were without active treatment. Treatment with anti‐CGRP medication was positively associated with a reduction in the HADS‐D ( β = 1.65, p = 0.01) compared to control, independent of MMD reduction. However, the same effect was not found for the CES‐D ( β = 2.15, p = 0.21). Active depression predicted poorer response to erenumab ( p = 0.02) but not to fremanezumab ( p = 0.09).

Conclusion

Anti‐CGRP (ligand or receptor) monoclonals lead to improvement of depressive symptoms in individuals with migraine, independent of migraine reduction. Depression may predict treatment response to erenumab but not to fremanezumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcitonin Gene-Related PeptideMigraine DisordersHumansLigandsDepressionHeadache

Stichwörter der Autor:innen

depressionmigrainepredictortreatment response

Substanzen

Calcitonin Gene-Related PeptideLigands

Autor:innen und Institutionen

  • Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
  • Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands.

ORCID-Profile: Simone de Vries Lentsch

Zitieren

APA

de Vries Lentsch, S., van der Arend, B. W. H., de Boer, I., van Zwet, E. W., MaassenVanDenBrink, A., & Terwindt, G. M. (2024). Depression and treatment with anti‐calcitonin gene related peptide ( CGRP) (ligand or receptor) antibodies for migraine. European Journal of Neurology, 31(2). https://doi.org/10.1111/ene.16106

Vancouver

de Vries Lentsch S, van der Arend BWH, de Boer I, van Zwet EW, MaassenVanDenBrink A, Terwindt GM. Depression and treatment with anti‐calcitonin gene related peptide ( CGRP) (ligand or receptor) antibodies for migraine. European Journal of Neurology. 2024;31(2). doi:10.1111/ene.16106

BibTeX
@article{deVriesLentsch2024,
  author = {de Vries Lentsch, Simone and van der Arend, Britt W H and de Boer, Irene and van Zwet, Erik W and MaassenVanDenBrink, Antoinette and Terwindt, Gisela M},
  title = {Depression and treatment with anti‐calcitonin gene related peptide ( CGRP) (ligand or receptor) antibodies for migraine},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {2},
  doi = {10.1111/ene.16106}
}
Kostenlos starten →